Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion type Assertion NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_head.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion description "[Possible carcinogenic mechanisms include imbalance between endometrial proliferation by unopposed estrogen and the mismatch repair (MMR) system; hypermethylation of the MMR gene hMLH1; mutation of PTEN, ?-catenin and K-ras genes in type I endometrial cancer and of HER-2/neu and p53 genes in type II endometrial cancer; hypermethylation of SPRY2, RASSF1A, RSK4, CHFR and CDH1; and methylation of tumor suppressor microRNAs, including miR-124, miR-126, miR-137, miR-491, miR-129-2 and miR-152.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_provenance.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion evidence source_evidence_literature NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_provenance.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion SIO_000772 25131761 NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_provenance.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion wasDerivedFrom befree-2016 NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_provenance.
- NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_assertion wasGeneratedBy ECO_0000203 NP1211479.RAVY1Tc2kDPkXT0dgmPFt8KnWgVEI3fCPp51cCXNWI0tY130_provenance.